BeiGene currently trades with a PEG ratio of 1.8, based on Sep 2, 2026 data. Dividing the 803.96 PE ratio by the 446.2% earnings growth rate produces this figure. Relative to the 19.74 average from the past 4 quarters, the PEG ratio has shrunk by 91%.
| Year | PEG ratio | PE ratio | Growth YoY |
|---|---|---|---|
| 2025 | 10.65 | 1,519.05 | 142.6% |
| 2024 | N/A | N/A | 27.7% |
| 2023 | N/A | N/A | 56.4% |
| 2022 | N/A | N/A | -23.1% |
| 2021 | N/A | N/A | 19.3% |
| 2020 | N/A | N/A | -23% |
| 2019 | N/A | N/A | -31.2% |
| 2018 | N/A | N/A | -447.1% |
| 2017 | N/A | N/A | 43.3% |
| 2016 | N/A | N/A | 42.3% |
| 2015 | N/A | N/A | -188.9% |
| 2014 | N/A | N/A | -125% |
| 2013 | N/A | N/A | N/A |
| Year | PEG ratio | PE ratio | Growth YoY |
|---|---|---|---|
| Jun 2026 | 1.42 | 633.27 | 446.2% |
| Mar 2026 | 3.68 | 824.92 | 224.1% |
| Dec 2025 | 10.65 | 1,519.05 | 142.6% |
| Sep 2025 | 63.21 | 6,814 | 107.8% |
| Jun 2025 | N/A | N/A | 66.7% |
| Mar 2025 | N/A | N/A | 50% |
| Dec 2024 | N/A | N/A | 27.7% |
| Sep 2024 | N/A | N/A | 9.9% |
| Jun 2024 | N/A | N/A | 69.5% |
| Mar 2024 | N/A | N/A | 59.2% |
| Dec 2023 | N/A | N/A | 56.4% |
| Sep 2023 | N/A | N/A | 57% |
| Jun 2023 | N/A | N/A | 20% |
| Mar 2023 | N/A | N/A | 10.1% |
| Dec 2022 | N/A | N/A | -23.1% |
With a PEG of 1.8, ONC ranks higher than the Healthcare sector and the industry average. In comparison with the Healthcare sector average of 0.57, BeiGene's PEG is 216% higher.
According to Sep 2, 2026 figures, ONC's PEG ratio stands at 1.8.
The PEG ratio derives from taking PE and dividing by the rate at which earnings are growing (YoY TTM). As of Sep 2, 2026, BeiGene carries a PE ratio of 803.96. Earnings grew at 446.2% over the TTM period ending Jun 2026. Applying the formula, this yields a PEG ratio of 1.8. PEG RATIO(1.8) = PE RATIO(803.96) / EPS GROWTH(446.2%)
All PEG ratio stats are based on quarterly TTM periods, unless otherwise specified.